Lead Product(s) : Posiphen tartrate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Buntanetap (posiphen tartrate) is an oral TINAPs, which mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. Currently being investigated for alzheimer's disease and parkinson's disease patients.
Product Name : Buntanetap
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Posiphen tartrate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Posiphen tartrate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Posiphen Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2010
Lead Product(s) : Posiphen tartrate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable